SCHEMBL194955

SCHEMBL194955

CN(C)c1ccc2cc(-c3ccccc3)c(=O)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.62
MIF P14174 1/20 0.62
RAB9A P51151 6/20 0.62
KDM4E B2RXH2 5/20 0.62
ALDH1A1 P00352 3/20 0.62
MAOB P27338 2/20 0.62
SLC16A3 O15427 1/20 0.59
PGR P06401 3/20 0.58
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
GLA P06280 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPT P10636 2/20 0.56
USP2 O75604 1/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 1/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL28308230 0.90 RAB9A (0.62) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL2687082 0.88 SLC16A3 (0.51) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL194256 0.85 CYP19A1 (0.79) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL4307998 0.85 SLC16A3 (0.52) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL14160789 0.85 NPC1 (0.58) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL4300702 0.84 ACHE (0.50) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL15216064 0.84 ALDH1A1 (0.69) NPC1RAB9AKDM4EALDH1A1MAOB
Bromide SCHEMBL4299197 0.83 SLC16A3 (0.51) NPC1MIFRAB9AKDM4EALDH1A1
Bromide SCHEMBL4309541 0.83 ALDH1A1 (0.50) NPC1MIFRAB9AKDM4EALDH1A1
SCHEMBL5590725 0.82 MIF (0.58) NPC1MIFRAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US claimed
CN-107652222-B Oxime ester photoinitiators 巴斯夫欧洲公司 2021-09-10 CN claimed
US-10919909-B2 Photoinitiated reactions LINTFIELD LIMITED (GB) 2021-02-16 US claimed
CN-105198793-B Oxime ester photoinitiators 巴斯夫欧洲公司 2019-08-13 CN claimed
US-20190211031-A1 PHOTOINITIATED REACTIONS LINTFIELD LIMITED (GB) 2019-07-11 US claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 EP claimed
CN-104284888-B Oxime ester photoinitiators 巴斯夫欧洲公司 2017-10-27 CN claimed
EP-4743828-A1 PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING BASF SE (DE) 2026-05-20 EP disclosed
US-20250149336-A1 PHOTORESIST COMPOSITION AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-05-08 US disclosed
CN-114129544-B Ultraviolet curable hydrogel resin for transdermal administration, hydrogel, and cataplasm comprising same Icure药品株式会社 2025-03-21 CN disclosed
CN-119403840-A Photocurable composition, method for producing cured film, solid-state imaging element, image display device, and radical polymerization initiator 富士胶片株式会社 2025-02-07 CN disclosed
WO-2025011754-A1 PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING BASF SE (DE) 2025-01-16 WO disclosed
EP-4114825-B1 OXIME ESTER PHOTOINITIATORS BASF SE (DE) 2024-11-20 EP disclosed
WO-2002100903-A1 OXIME ESTER PHOTOINITIATORS HAVING A COMBINED STRUCTURE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-12-19 WO disclosed
US-20020020832-A1 Photosensitive resin composition CIBA SPECIALTY CHEMICALS CORP. 2002-02-21 US disclosed
EP-1163553-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS Ciba SC Holding AG (CH) 2001-12-19 EP disclosed
US-20010012596-A1 For resist applications; thermostability, storage stability CIBA SPECIALTY CHEMICALS CORP. 2001-08-09 US disclosed
WO-2000052530-A1 OXIME DERIVATIVES AND THE USE THEREOF AS PHOTOINITIATORS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-09-08 WO disclosed
US-4250053-A WITH FLUORESCENT COMPOUND MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1981-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919909-B2 Photoinitiated reactions KMO, DECR1, PPOX NPC1 2000/4885MIF 4651/4885RAB9A 3269/4885
US-20190211031-A1 PHOTOINITIATED REACTIONS DOHH, PAH, DBH NPC1 2594/4885MIF 4053/4885RAB9A 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.